Literature DB >> 20197202

Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma.

K C Rissetto1, H Rindt2, K A Selting1, J A Villamil1, C J Henry3, C R Reinero4.   

Abstract

T regulatory cells (Tregs) are a unique subset of T helper cells that serve to modify/inhibit effector cells of the immune system and thus are essential to prevent autoimmunity. Overzealous Treg activity may contribute to impaired immune responses to cancer. Tregs can be phenotypically identified by proteins expressed on the cell surface (CD4 and CD25) and inside the cell (forkhead box3 (FoxP3)), although in dogs, no anti-canine CD25 antibody exists. We hypothesized that a mouse anti-human CD25 antibody definitively recognizes the canine protein and can be used to identify Tregs in dogs. We describe cloning and transfection of the canine CD25 gene into human HeLa cells with subsequent expression of the canine protein on the cell surface detected using an anti-human CD25 antibody in a flow cytometric assay. Validation of this antibody was used to identify CD4+CD25+FoxP3+ Tregs in 39 healthy dogs and 16 dogs with osteosarcoma (OSA). Results were expressed in five different ways and showed significantly fewer %CD4+CD25+ T lymphocytes expressing FoxP3 in blood of older dogs (>/=7 years) compared with the other two age groups (<2 and 2-6 years) (p<0.001) and fewer %CD4+CD25+FoxP3+ Tregs in the tumor draining lymph nodes of OSA patients compared to the unrelated lymph node (p=0.049). However, there was no significant difference in % Tregs in the peripheral blood or lymph nodes between the control dogs and those with OSA. While the CD25 antibody can be successfully used in a flow cytometric assay to identify Tregs, this study does not support clinical utility of phenotypic recognition of Tregs in dogs with OSA. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197202     DOI: 10.1016/j.vetimm.2010.02.002

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  7 in total

1.  Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog.

Authors:  Dammy Pinheiro; Yogesh Singh; Charlotte R Grant; Richard C Appleton; Flavio Sacchini; Kate R L Walker; Alden H Chadbourne; Charlotte A Palmer; Elizabeth Armitage-Chan; Ian Thompson; Lina Williamson; Fiona Cunningham; Oliver A Garden
Journal:  Immunology       Date:  2010-09-30       Impact factor: 7.397

2.  Immunohistochemical investigation of Foxp3 expression in the intestine in healthy and diseased dogs.

Authors:  Johannes Junginger; Ulrike Schwittlick; Frederik Lemensieck; Ingo Nolte; Marion Hewicker-Trautwein
Journal:  Vet Res       Date:  2012-03-22       Impact factor: 3.683

Review 3.  The immunotherapy of canine osteosarcoma: a historical and systematic review.

Authors:  K L Wycislo; T M Fan
Journal:  J Vet Intern Med       Date:  2015-04-30       Impact factor: 3.333

4.  Immune Function in Critically Ill Dogs.

Authors:  D Hoffman; J Amorim; A DeClue
Journal:  J Vet Intern Med       Date:  2017-11-13       Impact factor: 3.333

Review 5.  The immunopathology of sepsis: pathogen recognition, systemic inflammation, the compensatory anti-inflammatory response, and regulatory T cells.

Authors:  D H Lewis; D L Chan; D Pinheiro; E Armitage-Chan; O A Garden
Journal:  J Vet Intern Med       Date:  2012-03-17       Impact factor: 3.333

6.  T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma.

Authors:  Ellen E Sparger; Hong Chang; Ning Chin; Robert B Rebhun; Sita S Withers; Hung Kieu; Robert J Canter; Arta M Monjazeb; Michael S Kent
Journal:  Front Vet Sci       Date:  2021-12-02

7.  Serial changes of CD4+CD25+FoxP3+ regulatory T cell in canine model of sepsis induced by endotoxin.

Authors:  Dohyeon Yu; Junhwan Kim; Chul Park; Jinho Park
Journal:  J Vet Med Sci       Date:  2014-01-28       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.